Sheridan Gho and Michael Weaver, founders of Cenofex Innovations and 2016-2017 Rosenman Scholars, brought their company from New South Wales to the Bay Area to make connections and develop their technology: a device to treat lymphedema in breast cancer patients. Cenofex recently reported a $1.5M (Australian) seed investment to speed commercialization.
Cenofex Innovations has been awarded a $1.5M investment from the NSW 2018 Medical Devices Fund.
The NSW Medical Devices Fund is a competitive technology development and commercialisation program that aims to provide support to take local innovation to market. The fund is unique in its approach to provide substantial early funding support for technologies that are capable of improving patient care or health well-being and generating economic, social or environmental benefits to the state of NSW.
Cenofex Innovations was one of seven successful companies announced in the 2018 round, and one of three located in Wollongong (Hello medtech-innovation-hub!) The funds will accelerate our product development and enable us to complete early clinical trials. Most importantly, the funds will help Cenofex Innovations bring to market a medical device that will transform the treatment of lymphoedema.
For Cenofex Innovations, receiving these funds, following our successful NSW Health Rosenman Institute Fellowship, is particularly rewarding as it demonstrates faith in our causes and capability, and validates the work we conducted at that time.
We are delighted with this outcome, and look forward to delivering even bigger and better things with this support.